Publication
Title
IL-22-activated MUC13 impacts on colonic barrier function through JAK1/STAT3, SNAI1/ZEB1 and ROCK2/MAPK signaling
Author
Abstract
Overexpression of the transmembrane mucin MUC13, as seen in inflammatory bowel diseases (IBD), could potentially impact barrier function. This study aimed to explore how inflammation-induced MUC13 disrupts epithelial barrier integrity by affecting junctional protein expression in IBD, thereby also considering the involvement of MUC1. RNA sequencing and permeability assays were performed using LS513 cells transfected with MUC1 and MUC13 siRNA and subsequently stimulated with IL-22. In vivo intestinal permeability and MUC13-related signaling pathways affecting barrier function were investigated in acute and chronic DSS-induced colitis wildtype and Muc13−/− mice. Finally, the expression of MUC13, its regulators and other barrier mediators were studied in IBD and control patients. Mucin knockdown in intestinal epithelial cells affected gene expression of several barrier mediators in the presence/absence of inflammation. IL-22-induced MUC13 expression impacted barrier function by modulating the JAK1/STAT3, SNAI1/ZEB1 and ROCK2/MAPK signaling pathways, with a cooperating role for MUC1. In response to DSS, MUC13 was protective during the acute phase whereas it caused more harm upon chronic colitis. The pathways accounting for the MUC13-mediated barrier dysfunction were also altered upon inflammation in IBD patients. These novel findings indicate an active role for aberrant MUC13 signaling inducing intestinal barrier dysfunction upon inflammation with MUC1 as collaborating partner.
Language
English
Source (journal)
Cells
Publication
2023
ISSN
2073-4409
DOI
10.3390/CELLS12091224
Volume/pages
12 :9 (2023) , p. 1-25
Article Reference
1224
ISI
000987280100001
Pubmed ID
37174625
Medium
E-only publicatie
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Project info
Role of MUC13 signaling on epithelial barrier disruption in gastrointestinal disorders.
Therapeutic modulation of the gastrointestinal permeability-inflammation-pain axis.
A mucin isoform-based biomarker assay to improve follow-up and treatment of inflammatory bowel diseases (IBD) and gastrointestinal (GI) cancers.
A mucin mRNA isoform-based biomarker assay to improve treatment response in patients with inflammatory bowel diseases.
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identifier c:irua:196439
Creation 16.05.2023
Last edited 21.10.2024
To cite this reference